These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 33008497)

  • 1. Immunotherapy for Prostate Cancer: Treatments for the "Lethal" Phenotype.
    Slovin SF
    Urol Clin North Am; 2020 Nov; 47(4):469-474. PubMed ID: 33008497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for Metastatic Prostate Cancer: Current and Emerging Treatment Options.
    Chakravarty D; Huang L; Kahn M; Tewari AK
    Urol Clin North Am; 2020 Nov; 47(4):487-510. PubMed ID: 33008499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for Localized Prostate Cancer: The Next Frontier?
    Patel D; McKay R; Parsons JK
    Urol Clin North Am; 2020 Nov; 47(4):443-456. PubMed ID: 33008495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The evolving landscape of immunotherapy in advanced prostate cancer.
    Patel VG; Oh WK
    Immunotherapy; 2019 Jul; 11(10):903-912. PubMed ID: 31161846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapeutics for the treatment of prostate cancer: a patent landscape based on key therapeutic mechanisms of actions.
    Harris E
    Pharm Pat Anal; 2018 Jan; 7(1):47-57. PubMed ID: 29227196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy.
    Gomella LG; Gelpi-Hammerschmidt F; Kundavram C
    Can J Urol; 2014 Apr; 21(2 Supp 1):48-56. PubMed ID: 24775724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective combinatorial immunotherapy for castration-resistant prostate cancer.
    Lu X; Horner JW; Paul E; Shang X; Troncoso P; Deng P; Jiang S; Chang Q; Spring DJ; Sharma P; Zebala JA; Maeda DY; Wang YA; DePinho RA
    Nature; 2017 Mar; 543(7647):728-732. PubMed ID: 28321130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer.
    Fong L; Carroll P; Weinberg V; Chan S; Lewis J; Corman J; Amling CL; Stephenson RA; Simko J; Sheikh NA; Sims RB; Frohlich MW; Small EJ
    J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25255802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.
    Sinha M; Zhang L; Subudhi S; Chen B; Marquez J; Liu EV; Allaire K; Cheung A; Ng S; Nguyen C; Friedlander TW; Aggarwal R; Spitzer M; Allison JP; Small EJ; Sharma P; Fong L
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current role of immunotherapy for the treatment of prostate cancer.
    Porfyris O; Kalomoiris P
    J BUON; 2013; 18(4):809-17. PubMed ID: 24344002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients.
    Holl EK; McNamara MA; Healy P; Anand M; Concepcion RS; Breland CD; Dumbudze I; Tutrone R; Shore N; Armstrong AJ; Harrison M; Wallace JA; Wu Y; George DJ
    Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):588-592. PubMed ID: 30980027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes.
    Claps M; Mennitto A; Guadalupi V; Sepe P; Stellato M; Zattarin E; Gillessen SS; Sternberg CN; Berruti A; De Braud FGM; Verzoni E; Procopio G
    Cancer Treat Rev; 2020 Aug; 88():102057. PubMed ID: 32574991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.
    Wu YM; Cieślik M; Lonigro RJ; Vats P; Reimers MA; Cao X; Ning Y; Wang L; Kunju LP; de Sarkar N; Heath EI; Chou J; Feng FY; Nelson PS; de Bono JS; Zou W; Montgomery B; Alva A; ; Robinson DR; Chinnaiyan AM
    Cell; 2018 Jun; 173(7):1770-1782.e14. PubMed ID: 29906450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions.
    Wei XX; Fong L; Small EJ
    Expert Rev Vaccines; 2015; 14(12):1529-41. PubMed ID: 26488270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy.
    Mulders PF; De Santis M; Powles T; Fizazi K
    Cancer Immunol Immunother; 2015 Jun; 64(6):655-63. PubMed ID: 26025563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T.
    Quinn DI; Vaishampayan U; Higano CS; Lin DW; Shore ND; Beer TM
    Expert Rev Anticancer Ther; 2014 Jan; 14(1):51-61. PubMed ID: 24224900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?
    Ruiz de Porras V; Pardo JC; Notario L; Etxaniz O; Font A
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-coding RNAs: Emerging roles in the characterization of immune microenvironment and immunotherapy of prostate cancer.
    Yang F; Li J; Ge Q; Zhang Y; Zhang M; Zhou J; Wang H; Du J; Gao S; Liang C; Meng J
    Biochem Pharmacol; 2023 Aug; 214():115669. PubMed ID: 37364622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: Past and Future Strategies for Optimization.
    Reimers MA; Slane KE; Pachynski RK
    Curr Urol Rep; 2019 Sep; 20(10):64. PubMed ID: 31482315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing.
    Viswanathan SR; Ha G; Hoff AM; Wala JA; Carrot-Zhang J; Whelan CW; Haradhvala NJ; Freeman SS; Reed SC; Rhoades J; Polak P; Cipicchio M; Wankowicz SA; Wong A; Kamath T; Zhang Z; Gydush GJ; Rotem D; ; Love JC; Getz G; Gabriel S; Zhang CZ; Dehm SM; Nelson PS; Van Allen EM; Choudhury AD; Adalsteinsson VA; Beroukhim R; Taplin ME; Meyerson M
    Cell; 2018 Jul; 174(2):433-447.e19. PubMed ID: 29909985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.